[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337030-105":59,"doc-detail-337030-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","persistence-of-activated-anti-mesothelin-hyp218-chimeric-antigen-receptor-t-cells-in-the-tumour-is-associated-with-efficacy-in-gastric-and-colorectal-carcinomas","Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas","","Patients with advanced gastric and colorectal cancers have limited treatment options. Because mesothelin is highly expressed in these tumour types, the study assessed anti-mesothelin hYP218 CAR T cells alone and combined with anti-PD1 antibody pembrolizumab. GEPIA and TCGA were used to evaluate mesothelin mRNA expression, with further analyses by flow cytometry, cytotoxicity and cytokine release assays, and NSG xenograft models. hYP218 CAR T cells showed strong cytotoxicity, persisted in tumours functionally by day 40, maintained activation markers CD39 and CD69, increased IFN-γ and TNF-α, and enhanced efficacy in larger HGC27 tumours with pembrolizumab.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/persistence-of-activated-anti-mesothelin-hyp218-chimeric-antigen-receptor-t-cells-in-the-tumour-is-associated-with-efficacy-in-gastric-and-colorectal-carcinomas/337030/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/persistence-of-activated-anti-mesothelin-hyp218-chimeric-antigen-receptor-t-cells-in-the-tumour-is-associated-with-efficacy-in-gastric-and-colorectal-carcinomas/337030.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of this study?","Question",{"text":112,"@type":113},"To evaluate the therapeutic benefits of anti-mesothelin hYP218 CAR T cells alone and in combination with pembrolizumab (anti-PD1) for gastric and colorectal cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was mesothelin expression assessed in gastric and colorectal cancers?",{"text":117,"@type":113},"GEPIA analysis using TCGA tumor datasets evaluated mesothelin mRNA expression, and mesothelin expression in cell lines was analyzed by flow cytometry.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study report about CAR T cell persistence and activity in the tumour?",{"text":121,"@type":113},"Activated hYP218 CAR T cells persisted in the tumour microenvironment in a functional state at day 40, with increased activation markers CD39 and CD69, elevated IFN-γ and TNF-α production, and continued ability to kill tumour cells in vitro after tumour isolation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337030,1790094173,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":81,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10.1002/ctm2.70057  \nRESEARCH ARTICLE  \nPersistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas  \nSameer Mir1  Abhilash Venugopalan1  Jingli Zhang1  Nishanth Ulhas Nair2 Manjistha Sengupta1  Manakamana Khanal1  Chaido Stathopoulou1  Qun Jiang1  Raffit Hassan1   \n1Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA  \n2 Cancer Data Science Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA  \nCorrespondence  \nRaffit Hassan, MD, Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), 10-CCR Rm. 4E-5330 Bethesda, MD 20892, USA.  \n[Email:](Email: hassanr@mail.nih.gov)[ hassanr@mail.nih.gov](Email: hassanr@mail.nih.gov)  \nGraphical Abstract  \n∙ Mesothelin expression is significantly higher in gastric and colorectal cancers than normal tissues.  \n∙ hYP218 CAR T cells demonstrate strong anti-tumour activity against mesothelin-positive gastric and colorectal carcinomas.  \n∙ Activated hYP218 CAR T cells persist in the tumour microenvironment and retain their cytotoxic activity.  \n∙ Addition of pembrolizumab in larger tumours enhance CAR T cell efficacy.  \nClin. Transl. Med. 2024;14:e70057 .  \n[https://doi.org/10.1002/ctm2.70057](https://doi.org/10.1002/ctm2.70057)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nDOI: 10.1002/ctm2.70057  \nRESEARCH ARTICLE  \nPersistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas  \nSameer Mir1  Abhilash Venugopalan1  Jingli Zhang1  Nishanth Ulhas Nair2 Manjistha Sengupta1  Manakamana Khanal1  Chaido Stathopoulou1  Qun Jiang1  Raffit Hassan1   \n1Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA  \n2 Cancer Data Science Laboratory, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, USA  \nCorrespondence  \nRaffit Hassan, MD, Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), 10-CCR Rm. 4E-5330 Bethesda, MD 20892, USA. [Email:](Email: hassanr@mail.nih.gov)[ hassanr@mail.nih.gov](Email: hassanr@mail.nih.gov)  \nFunding information  \nIntramural Research Program of the NIH; National Cancer Institute; Center for Cancer Research, Grant/Award Number:  \nZIA-BC-010816  \nAbstract  \nPatients with advanced gastric and colorectal cancers have limited treatment options. Since mesothelin is highly expressed in these tumour types, we evaluated the therapeutic benefits of anti-mesothelin hYP218 CAR T cells alone, and in combination with anti-PD1 antibody, pembrolizumab.  \nGEPIA analysis was performed using human gastric (n = 408) and colon cancer tumours (n = 275) in TCGA database, to evaluate mRNA expression of mesothelin, compared to normal tissues. Mesothelin expression in gastric and colorectal cancer cell-lines (n = 5) was analysed using flow cytometry. In vitro efficacy by hYP218 CAR T cells was tested by cytotoxicity and cytokine release assays. In vivo anti-tumour efficacy of hYP218 CAR T cells alone, and in combination with pembrolizumab, was evaluated in NSG mice bearing human gastric (HGC27) and colorectal (SW48) tumour xenografts. Additionally, hYP218 CAR-T cell persistence, activation and exhaustion marker-expression were studied. Mesothelin expression was significantly higher in gastric and colon cancer biopsies compared to normal tissues (p \u003C .005) . Mesothelin expression in gastric and colon cancer cell lines ranged fr","cbCaisSiQVsotfJ1","https://ap.wps.com/l/cbCaisSiQVsotfJ1","pdf",7011257,21,"English","# Graphical Abstract\n# Abstract\n## Methods and evidence sources\n## In vitro and in vivo findings\n# Keywords\n# Highlights","[{\"question\":\"What was the main objective of this study?\",\"answer\":\"To evaluate the therapeutic benefits of anti-mesothelin hYP218 CAR T cells alone and in combination with pembrolizumab (anti-PD1) for gastric and colorectal cancers.\"},{\"question\":\"How was mesothelin expression assessed in gastric and colorectal cancers?\",\"answer\":\"GEPIA analysis using TCGA tumor datasets evaluated mesothelin mRNA expression, and mesothelin expression in cell lines was analyzed by flow cytometry.\"},{\"question\":\"What did the study report about CAR T cell persistence and activity in the tumour?\",\"answer\":\"Activated hYP218 CAR T cells persisted in the tumour microenvironment in a functional state at day 40, with increased activation markers CD39 and CD69, elevated IFN-γ and TNF-α production, and continued ability to kill tumour cells in vitro after tumour isolation.\"}]","Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas | PDF",1790017441,53,[147,151,155],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/6f3ae2a3d7af80c703ffdf2007f84a27.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/ad13d7f256426b4f00de187d703b67f9.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/111dba47b319b923f9b5cb27b0159efb.webp",981,1289]